Instrumento Inactivo

Otros idiomas Merrimack Pharmaceuticals Inc Nasdaq

Acciones

US5903281005

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution and Cash Liquidating Dividend Amount of $15.10 per Share of Common Stock	13/05
Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock	10/05
Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution	09/05
Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Payable on or About May 17, 2024	09/05
Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution	30/04
Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan	27/03
Merrimack Receives $225 Million Milestone Payment from Ipsen	27/03
Merrimack Reports Full Year 2023 Financial Results	07/03
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Merrimack Reports Ipsen Announcement of Approval by The US FDA of Onivyde Plus 5 Fluorouracil/Leucovorin and Oxaliplatin as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma	14/02
Merrimack Pharmaceuticals to Receive $225 Million Milestone Payment From Ipsen	14/02
Merrimack Pharmaceuticals to Get $225 Million Milestone Payment After FDA's Supplemental NDA Approval	13/02
Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)	13/02
Merrimack Pharmaceuticals Insider Bought Shares Worth $627,125, According to a Recent SEC Filing	16/11
Merrimack Reports Third Quarter 2023 Financial Results	02/11
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	02/11
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to S&P Global BMI Index	18/09/23
Insider Buy: Merrimack Pharmaceuticals	09/08/23
Merrimack Reports Second Quarter 2023 Financial Results	03/08/23
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	03/08/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Merrimack Pharmaceuticals Inc Nasdaq

Acciones

US5903281005

Otros idiomas

Filtros